Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Publication | Open Access

DOI Full Paper Access

746

Citations

References

2016

Year

Timothy M. Nywening, Andrea Wang‐Gillam, Dominic E. Sanford, Brian A. Belt, Roheena Z. Panni, Brian Cusworth, Adetunji T. Toriola, Rebecca Nieman, Lori A. Worley, Motoyo Yano,

The Lancet Oncology

Pancreatic CancerTumour-associated MacrophagesMedicineImmunologyCcr2 InhibitionImmune Checkpoint InhibitorAdvanced Pancreatic CancerAnti-cancer AgentCancer TreatmentOncologyRadiation Oncology